Landing page header.png

Investment Opportunity in Nanotechnology-based Cancer Drug Development

Private placement round is now open until the end of August 2021

ABOUT iNANOD

iNANOD, based in Oslo Cancer Cluster Incubator, is developing new technology in cancer treatment that relies on nano-vehicles to pack and cargo the payload drug in a controlled way.

 

This technology is expected to result in enhanced drug penetration and efficacy by delivering the right drug in the right tissues in the right amount and within the right time duration.

THE PROBLEM

As per the World Health Organization, 9.6 million people died from cancer in 2018 (1 out of 6 deaths worldwide). Today, cancer patients suffer from a high rate of undesired side effects while under chemotherapy. Most cancer drugs are not site-specific.

 

Max 0.2% of small molecule cancer drugs reach cancer cells, while the rest spread over the body and impart unintended adverse effects on healthy cells.

THE SOLUTION

NANOparticle2bw.jpg

An innovative platform technology for cancer drug-delivery with the potential to disrupt the cancer drugs market.

iNANOD's technology combines individually proven technologies to improve drug delivery and reduce side effects.

We detected the need to incorporate cutting-edge technology in modern cancer treatments and aims to add value by introducing accelerated uptake involving a time parameter.

Our objective is to develop a platform technology for shorter chemotherapy with fewer side effects.

OUR PROPOSAL

THE PEOPLE

BOARD MEMBERS

Portrait_004_Åge_Master.jpg

Åge Nærdal

Trained as a Pharmacist having more than 35 years of experience in leadership from pharmaceutical industry.

Chairman

Nalinava3.jpg
Linkedin icon.png

Nalinava Sengupta

Board Member & CEO

After 15 years of academic research in chemistry, turned entrepreneur for a mission.

Linkedin icon.png
Hilde2.jpg

Hilde Nilsen

Board Member

Professor in Department of Clinical Molecular Biology,  Head (Epigenetics), Akershus University Hospital.

Linkedin icon.png
Jørn.jpg

Jørn Lein-Mathisen

Board Member

Business angel. Business development and entrepreneurial experiences internationally over 28 years.

Linkedin icon.png
Per.jpg

Per Foss

Bio-organic chemistry doctorate having hugely diverse professional expertise in the industry.

Board Member

Linkedin icon.png

ADVISORS

Knut.jpg
Espen.jpg

25 years of experience in drug development. Involved in more than 1000 projects involving clinical trials and regulatory affairs as a Clinical Research Organization executive chairman.

Knut Smerud

Advisory Board Member

Linkedin icon.png

Espen Burum-Auensen

Advisory Board Member

Medical doctor with a PhD in the field of oncology. Various roles in the pharmaceutical and biotech industry including business development, clinical trial development, commercial operations, and medical affairs.

Linkedin icon.png
Tanima4.jpg
Portrait_003_Ketil_Master.jpg

Co-founder and is a postdoctoral research scientist in Department of Clinical Molecular Biology,  Akershus University Hospital.

Advisory Board Member

Tanima Sengupta

Linkedin icon.png

Ketil Wig

Strategic Advisor

An expert in strategy and corporate finance advisory, has executed and negotiated hundreds of projects and transactions within strategy and M&A and restructurings / turnarounds.

Linkedin icon.png
11039Gokce-110 h_Edit.jpg

Gokce Ataman

Financial Advisor

Senior finance professional with over 15 years of experience in M&A advisory and asset management.

Linkedin icon.png
Portrait_001_Ukjent_Master.jpg

Hilde Morris

Advisory Board Member

Studied veterinary medicine and led international clinical development programs. Advices iNANOD for pre-clinical research, management, and corporate governance.

Linkedin icon.png
Portrait_002_Arne_Master.jpg

Arne Rannestad

Advisory Board Member

A serial entrepreneur in health-tech. His focus area to contribute for iNANOD as an advisor on International market access, Business development, Start-up Management Strategy.

Linkedin icon.png
 

MILESTONES ACHIEVED

  • The technology has been reviewed scientifically by key opinion leaders in drug development in Norway.

  • Recent publications in scientific journals supporting iNANOD's underlying technology.

  • iNANOD filed a prophetic patent in the UK in April 2021

  • iNANOD established a strong board and advisory team bringing together experts with scientific and commercial expertise in drug development.

  • iNANOD also established collaborations with various industry partners including SINTEF Industry, Nordic Biosite, and Innoplexus.

  • Through these collaborations and also third-party CROs, iNANOD plans to run a very lean organization and cost structure.

SUPPORTERS

MEMBER OF

362ee937-ec3f-477c-afa9-568899afa683-w_9
Logo-OCC.png
IN_Logo.png
OIH Logo.jpg
Logo_OCC_I_E_lang_cmyk.png
LifeScience_4.png

SUBCONTRACTORS

Nordic Biosite Logo.jpg
Sintef Logo.png
innoplexus_logo_sticky.png

FUNDRAISING ROUND AND PURPOSE

 

iNANOD is raising NOK 5 million at a pre-money valuation of NOK 25 million. 

The Company previously raised ca. NOK 1.8 million in 2018 and 2019 in the previous rounds led by business angels.

If iNANOD is successful in reaching PoP, the Company will engage in further fundraising to fund regulatory preclinical development, phase I and phase II clinical trials, with a view to entering into a licensing deal with Big Pharma after phase IIb. A typical licensing deal includes an upfront payment, milestone payments, and royalty fees.

TAKE THE NEXT STEP

If you’re interested in investing in iNANOD, please enter your contact information below. We’ll get in touch with you.

Thank you for your interest in iNANOD! We will be in touch soon.